Top Markets
Coin of the day
Resverlogix Corp. Resverlogix Corp.

Resverlogix Corp.

RVX
Rangering i aksjer #28673
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Aksjekurs
$0.07339369
Sist synkronisert: 2026-08-18
Markedsverdi
$25.24M
Endring (1 dag)
5.26%
Endring (1 år)
-7.44%
Land
CA
Handel Resverlogix Corp. (RVX)

Kategori

P/B-forhold for Resverlogix Corp. (RVX)
P/B-forhold per 2026 TTM: 0
Ifølge Resverlogix Corp. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Resverlogix Corp. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 -
US
3.7087 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH